Compare LODE & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LODE | HURA |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 160.5M |
| IPO Year | 2004 | 2010 |
| Metric | LODE | HURA |
|---|---|---|
| Price | $1.78 | $1.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | ★ 1.5M | 230.8K |
| Earning Date | 11-02-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $303.79 | N/A |
| Revenue Next Year | $410.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $0.41 |
| 52 Week High | $4.98 | $3.43 |
| Indicator | LODE | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 24.01 | 51.28 |
| Support Level | N/A | $1.83 |
| Resistance Level | $3.32 | $2.22 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 12.90 | 54.61 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.